Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate ...

(TSX: TH) (NASDAQ: THTX), a biopharmaceutical firm with annual revenues of $85.87 million and an impressive 76% gross profit margin, has revealed study results indicating that ibalizumab ...

A Yale University study has found ibalizumab reduced viral replication and increased the count of immune cells in HIV patients, raising hopes for a new form of treatment for the disease.

Theratechnologies (THTX) presented data from a real-world, observational, registry study demonstrating the efficacy and safety of ibalizumab in ...

investigators from the Prospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) reported that ...

(RTTNews) - Theratechnologies Inc. (THTX) presented encouraging results from PROMISE-US, a Phase 4 study of ibalizumab in heavily treatment-experienced people with HIV, the company said in a ...

MONTREAL - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical firm with annual revenues of $85.87 million and an impressive 76% gross profit margin, has revealed study results ...

Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long ...